Dipexium Pharmaceuticals Inc  

(Public, NASDAQ:DPRX)   Watch this stock  
Find more results for Jack D. Duffy
10.32
-0.15 (-1.43%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.30 - 10.50
52 week 6.04 - 17.09
Open 10.50
Vol / Avg. 6,550.00/29,122.00
Mkt cap 107.44M
P/E     -
Div/yield     -
EPS -2.06
Shares 10.35M
Beta     -
Inst. own 28%
Aug 11, 2016
Q2 2016 Dipexium Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2016
Q1 2016 Dipexium Pharmaceuticals Inc Earnings Release
May 12, 2016
Q1 2016 Dipexium Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -78.08% -62.88%
Return on average equity -81.45% -66.05%
Employees 5 -
CDP Score - -

Address

14 Wall St., Suite 3D
NEW YORK, NY 10005
United States - Map
+1-212-2692834 (Phone)
+1-845-8183588 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). As a topical antibiotic, Locilex affects only the area to which it is applied, and does not spread to the entire body through the bloodstream, which is host to a number of different bacteria other than bacteria causing the skin infection. It is conducting over two Phase III clinical trials of Locilex for the treatment of Mild DFI (DPX-305 and DPX-306) in the United States. The Company has conducted over two separate Phase I skin irritation and skin sensitization studies. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a randomized, active-controlled double blind, multi-center clinical study in patients with Mild or Moderate DFI.

Officers and directors

Robert J. DeLuccia Executive Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
David P. Luci Esq. President, Chief Executive Officer, Secretary, Director
Age: 48
Bio & Compensation  - Reuters
Robert G. Shawah CPA Chief Accounting Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
David Garrett Vice President, Finance and Corporate Development, IR Contact Officer
Age: 39
Bio & Compensation  - Reuters
Jack Hugh Dean Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Michael E. Duffy Esq. Independent Director
Age: 45
Bio & Compensation  - Reuters
Thomas L. Harrison Independent Director
Age: 67
Bio & Compensation  - Reuters
Barry Kagan Independent Director
Age: 57
Bio & Compensation  - Reuters
William J. McSherry Jr., Esq. Independent Director
Age: 66
Bio & Compensation  - Reuters